Veterinary Vaccine Development · Klosterneuburg, Austria
Pioneering a Vaccine against Blackhead Disease in Turkeys.
Histovac GmbH is developing a groundbreaking live vaccine for the prevention of blackhead disease (histomonosis) in turkeys. A first-in-class answer to a re-emerging global threat for poultry health.
The Mission
Our mission
Based on decades of academic research, Histovac GmbH completes the development of a breakthrough vaccine to combat an unsolved poultry disease. From our headquarters in Klosterneuburg, Austria, we bridge the gap between scientific expertise and industrial-scale execution.
The disease
An Unmet Need in Poultry Health
Following the withdrawal of effective drugs, blackhead disease poses a substantial, uncontrolled threat to modern turkey production. Veterinarians and producers are currently left without any licensed preventative or curative tool.
Our Scientific Approach
We are centering our research around the complex biology of Histomonas meleagridis to deliver the worlds first live vaccine against a flagellate disease.
The Solution
A Live Vaccine against Blackhead Disease
Histovac GmbH introduces a live attenuated vaccine designed to immunize flocks before exposure. By filling a prophylactic gap the industry has been waiting on for decades, we aim to provide a scalable solution for turkey production.
The Roadmap
Regulatory Status
Our live vaccine is currently navigating the EU authorization process, backed by substantial efficacy and safety studies. We are preparing the ground for a registration in Europe and subsequent expansion to other markets.